Ottawa-Shanghai Joint School of Medicine


GU Leyi

Chief Physician, Doctoral Supervisor


Tel: 86-21-68383121


The main interest of research for the past two decades has been on biology of glomerular parietal epithelial cells and podocytes involved in progression of chronic kidney disease, with specific emphasis on proteinuria and glomerulosclerosis. The clinical interests has been on glomerular diseases, tumor associated nephropathy and complications of uremia. 

Dr Leyi Gu got MD from Shanghai Second medical University and PhD in Physiology at Juntendo University School of Medicine in Japan. He completed his further research training as visiting scholar at Mount Sinai School of Medicine in New York. He has worked at Renji Hospital since 1996. He was the first director of Renal Division in Kashgar Second People's Hospital of Xinjiang Province and the director of scientific research office in Renji Hospital. Currently, Dr Gu is the chief of Nephrology at Renji Hospital. He is the member of Nephrologists Branch of Shanghai Medical Doctor Association. Dr Gu has been funded by multiple National Nature Science Foundation Grant of China and National Nature Science Foundation Grant of Shanghai, and published more than 100 papers in the peer-reviewed scientific journals. He was the Shanghai Technology research leader. His major research areas include glomerular cell (podocytes and glomerular parietal epithelial cells) biology and immunology in uremia. His major clinical interests includes chronic kidney disease, glomerular disease, tumor associated nephropathy and complications of uremia.


  • Gu L, Hagiwara S, Fan Q, Tanimoto M, Kobata M, Yamashita M, Nishitani T, Gohda T, Ni Z, Qian J, Horikoshi S, Tomino Y. Role of Receptor for Advanced Glycation End-products and signaling events in Advanced Glycation End-products-induced Monocyte Chemoattractant Protein-1 expression in differentiated mouse podocytes. Nephrol Dial Transplant, 2006,21(2):299-313

  • Gu L, Ni Z, Qian J, Tomino Y. Pravastatin inhibit CML-induced MCP-1 expression in podocytes via prevention of signaling events. Nephron Exp Nephrol 2007,106(1):1-10

  • Gu L, Liang X, Wang L, Yan Y, Ni Z, Dai H, Gao J, Mou S, Wang Q, Chen X, Wang L, Qian J. Functional metabotropic glutamate receptors 1 and 5 are expressed in murine podocytes Kidney Int 2012,81(5):458-468

  • Gu L, Dai Y, Xu J, Mallipattu S, Kaufman L, Klotman PE, He JC, Chuang PY. Deletion of podocytes STAT3 mitigates the entire spectrum of HIV-1-associated nephropathy. AIDS 2013,27(7):1091-1098

  • Li X, Tao H, Xie K, Ni Z, Yan Y, Wei K, Chuang PY, He JC. Gu L. cAMP signaling prevents podocyte apoptosis via activation of protein kinase A and mitochondrial fusion. PLoS One 2014, 18;9(3):e92003. DOI 10.1371/journal. Pone.0092003

  • Tao H, Li X, Wei K, Xie K, Ni Z, Gu L. Cyclic AMP prevents decrease of phosphorylated ezrin/radixin/moesin and chloride intracellular channel 5 expressions in injured podocytes. Clin Exp Nephrol, 2015 DOI 10.1007/S10157-015-1102-6(IF=1.945)

  • Lu R, Estremadoyro C, Chen X, Zhu M, Ribeiro LC, Yan Y, Brendolan A, Fang W, Crepaldi C, Ni Z, Gu L, Ronco. Hemodialysis versus peritoneal dialysis: an observational study in two international centers. Int J Artif Organs. 2017 Nov 8:0. Doi: 10.5301/ijao.5000656

  • Guo X, Shi Y, Xie H, Zhang L, Xue G, Gu L, Hao C, Yang S, Kan K. Left innominate vein stenosis in an asymptomatic population : a restrospective analysis of 212 cases. Eur J Med Res. 2017,22(1):2.doi:10.1186/s40001-017-0243-3

  • Xie K, Zhu M, Xiang P, Chen X, Kasimumali A, Lu R, Wang Q, Mou S, Ni Z, Gu L, Pang H. PKA/CREB signaling prevents Adriamycin-induced podocyte apoptosis via upregulation of mitochondrial respiratory chain complexes. Mol Cell Biol 2018,38:e00181-17

  • Qian Y, Guo X, Yan Y, Che L, Guan X, Wu B, Lu R, Zhu M, Pang H, Ni Z, Gu L. Klotho reduces necroptosis by targeting oxidative stress involved in renal ischemia-reperfusion injury. Cell Physiol Biochem, 2018, in press. (IF=5.103)

  • Lu R, Xu C, Li Y, Yu L, Shao X, Xie K, Gu J, Yu Z, Yan Y, Guan Y, Ni Z, Ronco C, Gu L. The incidence prognosis and risk factors of cognitive impairment in maintenance haemodialysis patients. Blood Purif. 2018, 9(10):983. doi:10.1038/s41419-018-1023x

  • Fan Q, Lu R, Zhu M, Yan Y, Guo X, Qian Y, Zhang L, Dai H, Ni Z, Gu L. Serum miR-192 is related to tubulointerstitial lesion and short-term disease progression in IgA nephropathy. Nephron 2019 Feb 26:1-13. doi:10.1159/000497488.(IF=2.085)

  • Zhu M, Wang J, Wang Q, Xie K, Wang M, Qian C, Deng Y, Han L, Gao Y, Ni Z, Xia Q, Gu L. The incidence and risk factors of low oxygenation after orthotropic liver transplantation. Ann Transplant 2019 Mar 12;24:139-146. doi:10.12659/AOT.913716.(IF=1.369)

  • Xu C, Kasimumali A, Guo X, Lu R, Xie K, Zhu M, Qian Y, Chen X, Pang H, Wang Q, Fan Z, Dai H, Mou S, Ni Z, Gu L. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease. Nephrology (carlton). 2019 may 17. doi:10.1111/nep.13606.(IF=1.913)

  • Qian Y, Che L, Yan Y, Lu R, Zhu M, Xue S, Ni Z, Gu L. Urine Klotho is an early biomarker for acute kidney injury and predicts poor renal outcome after cardiac surgery. BMC Nephrology. 2019 Jul 17:20(1):268. Doi:10.1186/s12882-019-1460-s (IF=2.088)

  • Xu C, Kasimumali A, Guo X, Lu R, Xie K, Zhu M, Qian Y, Chen X, Pang H, Wang Q, Fan Z, Dai H, Mou S, Ni Z, Gu L. Reduction of mitochondria and up regulation of pyruvate dehydrogenase kinase 4 of skeletal muscle in patients with chronic kidney disease. Nephrology (carlton). 2020 Mar; 25(3):230-238. doi:10.1111/nep.13606.(IF=2.506)

  • Xie K, Xu C, Zhang M, Wang M, Min L, Qian C, Wang Q, Ni Z, Mou S, Dai H, Pang H, Gu L. Yes-associated protein regulates podocyte cell cycle re-entry and dedifferentiation in adriamycin-induced nephropathy. Cell Death Dis. 2019, Dec 4;10(12):915, doi:10.1038/s4149-019-2139-3 (IF=8.469)

  • Qian Y, Qian C, Xie K, Fan Q, Yan Y, Lu R, Wang L, Zhang M, Wang Q, Mou S, Dai H, Ni Z, Pang H, Gu L. P2X7 receptor signaling promotoes inflammation in renal parenchymal cells suffering from ischemia-reperfusion injury. Cell Death Dis 2021,12:132. Doi:10.1038/s41419-020-03384-y (IF=8.469)

  • Lu R, Gu LY, Zhang W, Guo Y, Zang X, Zhou Y, Yu L, Pan S, Pang H, Liu S, Xie K, Li P, Zeng X, Lu Y. Protocol for thiamine and folic acid in the treatment of cognitive impairment in maintenance haemodialysis patients: a prospective, randomised, placebo-controlled, double-blind, multicentre study. BMJ Open. 2021 Dec 14;11(12):e050605. doi: 10.1136/bmjopen-2021-050605

  • Lu R, Fang Y, Zhou Y, Che M, Shen J, Liu Q, Zhang H, Pan S, Lin Y, Wang Q, Mou S, Ni Z, Gu L. A pilot study of thiamin and folic acid in hemodialysis patients with cognitive impairment.  Ren Fail. 2021 Dec;43(1):766-773. doi: 10.1080/0886022X.2021.1914656.